Skip to content
Shameless Cloning

Search Shameless Cloning

Search superinvestors, stocks, insiders and members of Congress

Q2 2026 13F · SEC CIK 1600004

First Light Asset Management, LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value
$1.6B
Reported positions
31
Top holdings a year, 3 yrs
+23.6%
Assets under management
$1.4B

First Light Asset Management, LLC is a hedge fund that reported 31 positions worth $1.6B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Neogenomics Inc (NEO, 10.9%), SI-BONE Inc (SIBN, 8.1%), Axogen Inc (AXGN, 7.7%). A portfolio copying its top holdings returned 23.6% a year over the last 3 years, against 20.4% for the S&P 500.

First Light Asset Management, LLC holdings all 31 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

First Light Asset Management, LLC 13F holdings
Stock% of 13F valueShare changeReported value
NEONeogenomics Inc10.9%+26.2%$179.2M
SIBNSI-BONE Inc8.1%+51.8%$132.6M
AXGNAxogen Inc7.7%-31.3%$126.9M
APGEApogee Therapeutics Inc7.5%+61.3%$123.5M
PVLAPalvella Therapeutics Inc Ne7.2%-21.3%$118.0M
TWSTTwist Bioscience Corp4.6%-17.2%$74.9M
ELVNEnliven Therapeutics Inc4.2%+574.1%$69.1M
GHGuardant Health Inc4.0%+57.5%$66.3M
MASS908 Devices Inc3.3%+3.5%$54.7M
AMLXAmylyx Pharmaceuticals Inc3.3%-5.2%$54.3M
WGSGenedx Holdings Corp3.3%+222.7%$53.8M
SLPSimulations Plus Ord3.1%+6.1%$51.1M
TNDMTandem Diabetes Care Inc3.1%+157.4%$51.1M
CRNXCrinetics Pharmaceuticals in3.1%+24.9%$50.9M
NPCENeuropace Inc2.8%+16.3%$45.5M
EWTXEdgewise Therapeutics Inc2.7%+9.3%$44.5M
ANABAnaptysbio Inc2.4%+2.9%$39.3M
TRVITrevi Therapeutics Inc2.4%—$39.1M
SEPNSepterna Inc2.0%+31.4%$32.3M
TLSITrisalus Life Sciences Inc1.8%+29.3%$29.8M
TECXTectonic Therapeutic Inc1.7%+23.6%$27.5M
HCATHealth Catalyst Inc1.6%-0.5%$25.5M
BFLYButterfly Network Inc1.4%-0.7%$22.2M
ESTAEstablishment Labs Hldgs Inc1.3%-19.9%$21.2M
PCVXVaxcyte Inc1.2%+143.4%$20.1M
IRTCIrhythm Technologies Inc1.2%-0.6%$19.9M
OMCLOmnicell Com1.1%-7.7%$18.8M
ATRCAtriCure, Inc.1.0%-22.2%$15.9M
KRMDKORU Medical Systems0.9%-10.1%$14.2M
TCMDTactile Sys Technology Inc0.8%—$13.8M
RYTMRhythm Pharmaceuticals Inc0.6%-1.6%$9.5M

What First Light Asset Management, LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Added to

Reduced

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year
+119.9% /yr
S&P 500 +20.1%
3 years
+23.6% /yr
S&P 500 +20.4%
5 years
+10.3% /yr
S&P 500 +11.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter13F valuePositions
Q2 2026$1.6B31
Q1 2026$1.1B35
Q4 2025$1.3B33
Q3 2025$1.1B41
Q2 2025$771.3M38
Q1 2025$875.7M37
Q4 2024$1.0B36
Q3 2024$1.2B38
Q2 2024$1.1B44
Q1 2024$1.3B50
Q4 2023$1.2B75
Q3 2023$1.1B75

Questions about First Light Asset Management, LLC's portfolio

What stocks does First Light Asset Management, LLC own?

First Light Asset Management, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 31 positions worth $1.6B. The largest are Neogenomics Inc (NEO) at 10.9%, SI-BONE Inc (SIBN) at 8.1%, Axogen Inc (AXGN) at 7.7%, Apogee Therapeutics Inc (APGE) at 7.5% and Palvella Therapeutics Inc Ne (PVLA) at 7.2%.

What did First Light Asset Management, LLC buy last quarter?

In Q2 2026, First Light Asset Management, LLC added a new position in Trevi Therapeutics Inc (TRVI), a new position in Tactile Sys Technology Inc (TCMD), Enliven Therapeutics Inc (ELVN) (+574.1% shares), Genedx Holdings Corp (WGS) (+222.7% shares) and Tandem Diabetes Care Inc (TNDM) (+157.4% shares), compared with its Q1 2026 filing.

What did First Light Asset Management, LLC sell last quarter?

In Q2 2026, First Light Asset Management, LLC sold all of Centessa Pharmaceuticals PLC (CNTA), sold all of Wave Life Sciences Ltd (WVE), sold all of Vera Therapeutics Inc Class A (VERA), sold all of Mimedx Group Inc (MDXG), sold all of Spyglass Pharma Inc (SGP), Axogen Inc (AXGN) (-31.3% shares), AtriCure, Inc. (ATRC) (-22.2% shares) and Palvella Therapeutics Inc Ne (PVLA) (-21.3% shares), compared with its Q1 2026 filing.

How has First Light Asset Management, LLC's portfolio performed?

A portfolio copying First Light Asset Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +23.6% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +119.9% against +20.1%. Over 5 years: +10.3% a year against +11.6%.

When is First Light Asset Management, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. First Light Asset Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does First Light Asset Management, LLC manage?

First Light Asset Management, LLC reported $1.4B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $1.6B.